Royalty Pharma annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma R&D Spending Growth & History (RPRX)
Royalty Pharma's r&d spending was $452.0M for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $452.0M | $450.0M | +22500.00% |
| 2024 | 2024-12-31 | $2.0M | −$50.0M | −96.15% |
| 2023 | 2023-12-31 | $52.0M | −$125.1M | −70.64% |
| 2022 | 2022-12-31 | $177.1M | −$23.0M | −11.48% |
| 2021 | 2021-12-31 | $200.1M | $173.8M | +661.09% |
| 2020 | 2020-12-31 | $26.3M | −$56.7M | −68.34% |
| 2019 | 2019-12-31 | $83.0M | −$309.6M | −78.85% |
| 2018 | 2018-12-31 | $392.6M | — | — |
Royalty Pharma quarterly r&d spending
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $97.9M | −$202.6M | −67.44% |
| Q1 2026 | 2026-03-31 | $39.8M | −$10.7M | −21.21% |
| Q4 2025 | 2025-12-31 | $50.5M | $50.0M | +10000.00% |
| Q3 2025 | 2025-09-30 | $50.5M | $50.0M | +10000.00% |
| Q2 2025 | 2025-06-30 | $300.5M | $300.0M | +60000.00% |
| Q1 2025 | 2025-03-31 | $50.5M | $50.0M | +10000.00% |
| Q4 2024 | 2024-12-31 | $500,000 | $0 | 0.00% |
| Q3 2024 | 2024-09-30 | $500,000 | −$50.0M | −99.01% |
| Q2 2024 | 2024-06-30 | $500,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $500,000 | $0 | 0.00% |
| Q4 2023 | 2023-12-31 | $500,000 | −$50.0M | −99.01% |
| Q3 2023 | 2023-09-30 | $50.5M | $25.0M | +98.04% |
| Q2 2023 | 2023-06-30 | $500,000 | −$106,000 | −17.49% |
| Q1 2023 | 2023-03-31 | $500,000 | −$100.0M | −99.50% |
| Q4 2022 | 2022-12-31 | $50.5M | −$53.3M | −51.36% |
| Q3 2022 | 2022-09-30 | $25.5M | −$65.0M | −71.82% |
| Q2 2022 | 2022-06-30 | $606,000 | −$2.5M | −80.59% |
| Q1 2022 | 2022-03-31 | $100.5M | $97.9M | +3705.38% |
| Q4 2021 | 2021-12-31 | $103.8M | — | — |
| Q3 2021 | 2021-09-30 | $90.5M | $85.4M | +1675.90% |
| Q2 2021 | 2021-06-30 | $3.1M | −$2.7M | −45.95% |
| Q1 2021 | 2021-03-31 | $2.6M | −$5.0M | −65.43% |
| Q3 2020 | 2020-09-30 | $5.1M | −$17.6M | −77.57% |
| Q2 2020 · Jun 30 | 2020-06-30 | $5.8M | −$15.7M | −73.08% |
| Q1 2020 | 2020-03-31 | $7.6M | — | — |
| Q3 2019 | 2019-09-30 | $22.7M | — | — |
| Q2 2019 | 2019-06-30 | $21.5M | — | — |
Royalty Pharma r&d spending trends
Over the last five fiscal years, Royalty Pharma's r&d spending increased from $26.3M to $452.0M, a change of $425.7M. The latest reported quarter, Q2 2026, shows $97.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗